New Drug Therapy Helps with Crohn’s Disease
(Ivanhoe Newswire) – A new drug therapy has been shown to reduce the effects of Crohn’s disease in 40 percent of patients who were treated with the drug in a trial.
The trial included over 1,000 patients who were randomly assigned a placebo, or the intravenous vedolizumab therapy, for a period of two weeks. Patients who showed any remission during that period were then reassigned to receive a placebo or the therapy every four to eight weeks for one year. After that period, nearly 40 percent of patients who received the therapy showed remission, compared to only 21 percent who were given the placebo. The study did note that adverse reactions were more common in the patients who were given vedolizumab.
For more information, go to: http://www.nejm.org/doi/full/10.1056/NEJMoa1215739
SOURCE: New England Journal of Medicine, August 2013
Click Here for a free weekly email with Ivanhoe's latest Medical Breakthroughs.